ESKATA™ is now approved for the treatment of raised seborrheic keratoses.
For external, topical use only
By a healthcare provider
Self-pay billing model
Register for Updates
ESKATA will be available to healthcare providers in the spring of 2018.
Pre-ordering will be available 2 weeks prior to product availability. To sign up to pre-order, register here.
Watch the ESKATA Application video
Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunodermatology. The company is focused on market segments with no FDA-approved medications or where treatment gaps exist.
What is ESKATA and what is its indication?
ESKATA is the first and only FDA-approved topical treatment that is indicated for raised seborrheic keratoses. It is a proprietary formulation with high-concentration hydrogen peroxide as the active ingredient.
When will ESKATA be available?
ESKATA will be available for the treatment of raised seborrheic keratoses in the spring of 2018. Click here to receive updates about ESKATA availability.
Is it necessary to become certified in the administration of ESKATA?
Certification is not required prior to purchase or use, but it is recommended that healthcare providers review the application technique in the ESKATA prescribing information.
What are the storage and handling requirements for ESKATA?
ESKATA should be stored at controlled room temperature (68ºF-77ºF). Shelf life is up to 2 years. ESKATA requires no refrigeration.